Drug Trial Radar · NCT07435038
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Dec 28, 2028
Study completion Oct 28, 2029
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Solid Tumors
Interventions
BPI-572270Drug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: up to 2 tears
- RP2DTime frame: up to 2 tears
- ORRTime frame: up to 3 tears
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Blacktown Hospital
Blacktown, New South Wales, Australia · Not yet recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Not yet recruiting
GenesisCare St Leonards, 7 Westbourne St, St Leonards
Sydney, New South Wales, Australia · Not yet recruiting
Southern Oncology Clinical Research Unit (SOCRU)
Bedford Park, South Australia, Australia · Not yet recruiting
Warringal Private Hospital
Heidelberg, Victoria, Australia · Not yet recruiting
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.